Navigating Complex Life Sciences Transactions With Precision
Distinguished by experienced leaders in the context of long-term relationships. MTS’s goal is to deliver a superior value proposition for our clients.
20+ Years of Advising Successful Outcomes With Life Sciences Clients
MTS Health Partners drives life sciences growth through expert strategic M&A and innovative financing solutions for transformational businesses.
Mergers, Acquisitions & Strategic Advisory
Sell-side Advisory
Buy-side Advisory
Cross Border M&A
Strategic Advisory
Large Pharma
Biotechnology
Specialty Pharma
Financing & Capital Markets
Negotiated Financing Across Equity Offering Types
Private VC Rounds
PIPEs
CMPOs
High-Touch, Customized Financing Process
Specialize in Shareholder Building & Expansion
Select Life Sciences Transactions
Mergers, Acquisitions & Strategic Advisory
Zymeworks Inc. enters into a definitive agreement to acquire Theravance Biopharma, Inc. for $929mm
Mergers, Acquisitions & Strategic Advisory
MTS served as financial advisor to Galapagos’ Independent Board of Directors on its collaboration agreement with Gilead Sciences for Ouro Medicines’ assets
Mergers, Acquisitions & Strategic Advisory
MTS served as exclusive financial advisor to Neurocrine Biosciences, on its divestment of its European commercial business (Neurocrine Group Limited) to Immedica Pharma
Mergers, Acquisitions & Strategic Advisory
MTS served as exclusive financial advisor to Opsidio on its sale of sole asset, OpSCF, to Insmed (NASDAQ: INSM)
